Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Transforming growth factor-β (TGF-β) and programmed death ligand 1 (PD-L1) are key immunosuppressive factors in the tumor microenvironment (TME).
• Dysregulated TGF-β signaling promotes tumor progression, while PD-L1 inactivates cytotoxic T cells, hindering anti-tumor immunity.
• Resistance to anti-PD-L1 therapies is often linked to TGF-β signaling within the TME.

Purpose of the Study:

• To review the roles of TGF-β and PD-L1 pathways in cancer immunity.
• To explore clinical strategies combining TGF-β and PD-L1 inhibition for cancer treatment.
• To evaluate dual-targeting agents for simultaneous blockade of these pathways.

Main Methods:

• Literature review of TGF-β and PD-L1 signaling in cancer.
• Analysis of current and emerging combination therapies.
• Discussion of bifunctional agents, including bintrafusp alfa.

Main Results:

• TGF-β and PD-L1 pathways exhibit complementary immunosuppressive functions in the TME.
• Combination therapies targeting both pathways show potential to enhance anti-tumor responses.
• Bintrafusp alfa represents a novel bifunctional agent for simultaneous TGF-β and PD-L1 inhibition.

Conclusions:

• Simultaneous, colocalized inhibition of TGF-β and PD-L1 pathways may improve efficacy and reduce toxicity of cancer immunotherapies.
• Dual-targeting agents offer a promising approach to overcome resistance mechanisms in cancer treatment.
• Further clinical investigation of bintrafusp alfa and similar agents is warranted.